Review ArticlesAdvances in Classification and Treatment of Non-Hodgkin Lymphoma Mantle CellRule, Simon BM, BS∗; Johns, Sophie MB, BS†Author Information From the ∗Plymouth University Medical School †University Hospital Plymouth, Plymouth, United Kingdom. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Simon Rule, BM, BS, Plymouth University Medical School, Plymouth Science Park, Research Way, Plymouth PL6 8BT, United Kingdom. E-mail: Simon.firstname.lastname@example.org. The Cancer Journal: 7/8 2020 - Volume 26 - Issue 4 - p 348-356 doi: 10.1097/PPO.0000000000000462 Buy Metrics Abstract Mantle cell lymphoma is a rare, aggressive, and largely incurable form of non-Hodgkin lymphoma. There are a number of well-characterized prognostic features but nothing that can help guide therapy. Treatment with chemotherapy is generally effective in the short term, but relapse is inevitable and subsequent treatment is challenging. The use of Bruton tyrosine kinase inhibitors, however, has transformed practice. These agents are highly active in relapsed disease and are very well-tolerated drugs. Chemotherapy-free combinations using Bruton tyrosine kinase inhibitors look very exciting and will likely evolve to be part of frontline care in the future. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.